Second-line treatment after disease progression following first-line chemotherapy with modified FOLFIRINOX in advanced pancreatic cancer patients

被引：1
|
作者：
Vivaldi, C. [1 ]
Vasile, E. [1 ]
Fornaro, L. [1 ]
Caparello, C. [1 ]
Musettini, G. [1 ]
Pasquini, G. [1 ]
Lencioni, M. [2 ]
Ricci, S. [2 ]
Falcone, A. [1 ]
机构：
[1] Azienda Osped Univ Pisana, UO Oncol Med Univ 2, Pisa, Italy
[2] Azienda Osped Univ Pisana, UO Oncol Med Osped 1, Pisa, Italy
来源：
EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷
关键词：
D O I：
10.1016/S0959-8049(16)31278-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2362
引用
收藏
页码：S456 / S457
页数：2
相关论文
共 50 条
  • [1] Second-line chemotherapy after disease progression following first-line FOLFOXIRI in advanced pancreatic cancer patients
    Vasile, E.
    Vivaldi, C.
    Fornaro, L.
    Caparello, C.
    Musettini, G.
    Pasquini, G.
    Catanese, S.
    Lencioni, M.
    Ricci, S.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2015, 26 : 98 - 98
  • [2] Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline resectable and locally advanced pancreatic adenocarcinoma
    Yoon, Hyunseok
    Shin, Yeokyeong
    Ryoo, Baek-Yeol
    Jeong, Hyehyun
    Park, Inkeun
    Seo, Dong-Wan
    Lee, Sang Soo
    Park, Do Hyun
    Song, Tae Jun
    Oh, Dongwook
    Hwang, Dae Wook
    Lee, Jae Hoon
    Song, Ki Byung
    Park, Yejong
    Kwak, Bong Jun
    Hong, Seung-Mo
    Park, Jin-hong
    Kim, Song Cheol
    Kim, Kyu-pyo
    Yoo, Changhoon
    PANCREATOLOGY, 2024, 24 (03) : 424 - 430
  • [3] Second-Line Gemcitabine Plus Nab-Paclitaxel for Patients with Unresectable Advanced Pancreatic Cancer after First-Line FOLFIRINOX Failure
    Mita, Naoki
    Iwashita, Takuji
    Uemura, Shinya
    Yoshida, Kensaku
    Iwasa, Yuhei
    Ando, Nobuhiro
    Iwata, Keisuke
    Okuno, Mitsuru
    Mukai, Tsuyoshi
    Shimizu, Masahito
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (06)
  • [4] Retrospective analysis of second-line chemotherapy after Folfirinox failure in advanced pancreatic cancer
    Chikhareva, Y.
    Fedyanin, M.
    Bazin, I.
    Pokataev, I.
    Manukyan, M.
    Kantieva, D.
    Tryakin, A.
    ANNALS OF ONCOLOGY, 2023, 34 : S131 - S131
  • [5] Taxol as second-line treatment in patients with advanced ovarian cancer after platinum-based first-line chemotherapy
    Mayerhofer, K
    Kucera, E
    Zeisler, H
    Speiser, P
    Reinthaller, A
    Sevelda, P
    GYNECOLOGIC ONCOLOGY, 1997, 64 (01) : 109 - 113
  • [6] Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer
    Shun Yamamoto
    Kengo Nagashima
    Takeshi Kawakami
    Seiichiro Mitani
    Masato Komoda
    Yasushi Tsuji
    Naoki Izawa
    Kentaro Kawakami
    Yoshiyuki Yamamoto
    Akitaka Makiyama
    Kentaro Yamazaki
    Toshiki Masuishi
    Taito Esaki
    Takako Eguchi Nakajima
    Hiroyuki Okuda
    Toshikazu Moriwaki
    Narikazu Boku
    BMC Cancer, 21
  • [7] Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer
    Yamamoto, Shun
    Nagashima, Kengo
    Kawakami, Takeshi
    Mitani, Seiichiro
    Komoda, Masato
    Tsuji, Yasushi
    Izawa, Naoki
    Kawakami, Kentaro
    Yamamoto, Yoshiyuki
    Makiyama, Akitaka
    Yamazaki, Kentaro
    Masuishi, Toshiki
    Esaki, Taito
    Nakajima, Takako Eguchi
    Okuda, Hiroyuki
    Moriwaki, Toshikazu
    Boku, Narikazu
    BMC CANCER, 2021, 21 (01)
  • [8] Progression-free survival in first-line chemotherapy is a prognostic factor in second-line chemotherapy in patients with advanced gastric cancer
    Kenji Hashimoto
    Atsuo Takashima
    Kengo Nagashima
    Shun-suke Okazaki
    Takako Eguchi Nakajima
    Ken Kato
    Tetsuya Hamaguchi
    Yasuhide Yamada
    Yasuhiro Shimada
    Journal of Cancer Research and Clinical Oncology, 2010, 136 : 1059 - 1064
  • [9] Progression-free survival in first-line chemotherapy is a prognostic factor in second-line chemotherapy in patients with advanced gastric cancer
    Hashimoto, Kenji
    Takashima, Atsuo
    Nagashima, Kengo
    Okazaki, Shun-suke
    Nakajima, Takako Eguchi
    Kato, Ken
    Hamaguchi, Tetsuya
    Yamada, Yasuhide
    Shimada, Yasuhiro
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2010, 136 (07) : 1059 - 1064
  • [10] Second-line treatment with modified FOLFIRINOX in patients with pancreatic adenocarcinoma who have failed first-line treatment with gemcitabine and nab-paclitaxel
    McSweeney, T.
    Das, A.
    O'Mahony, A.
    O'Tighearnaigh, F.
    O'Byrne, L.
    Feely, M.
    Passmore, E.
    Keane, S.
    Lanigan, S.
    Fitzgerald, S.
    Browne, T.
    De Beer, V.
    Dean, A.
    ANNALS OF ONCOLOGY, 2023, 34 : S133 - S133
12345